Unchanged pharmacokinetics of VP-16-213 (etoposide, NSC 141540) during concomitant administration of doxorubicin and cyclophosphamide

J. Van Hoogenhuijze; J. Lankelma; J. Stam; H. M. Pinedo

doi:10.1016/0277-5379(87)90283-5

Unchanged pharmacokinetics of VP-16-213 (etoposide, NSC 141540) during concomitant administration of doxorubicin and cyclophosphamide

J. Van Hoogenhuijze, J. Lankelma, J. Stam, H. M. Pinedo

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

In patients with small-cell lung cancer VP-16-213 is often given in combination with doxorubicin and cyclophosphamide. Little is known about possible interactions between these drugs. Therefore we investigated in 7 patients the pharmacokinetics of VP-16-213, with and without the other two drugs. We found no change in the pharmacokinetics. We also provide evidence that the pharmacokinetics did not change in two sequential administrations of the drug. Pharmacokinetic data are in agreement with previous reports.

Original language	English (US)
Pages (from-to)	807-811
Number of pages	5
Journal	European Journal of Cancer and Clinical Oncology
Volume	23
Issue number	6
DOIs	https://doi.org/10.1016/0277-5379(87)90283-5
State	Published - 1987
Externally published	Yes

ASJC Scopus subject areas

Oncology

Access to Document

10.1016/0277-5379(87)90283-5

Cite this

@article{8fea61a9417143d9a750eca79624ffb7,

title = "Unchanged pharmacokinetics of VP-16-213 (etoposide, NSC 141540) during concomitant administration of doxorubicin and cyclophosphamide",

abstract = "In patients with small-cell lung cancer VP-16-213 is often given in combination with doxorubicin and cyclophosphamide. Little is known about possible interactions between these drugs. Therefore we investigated in 7 patients the pharmacokinetics of VP-16-213, with and without the other two drugs. We found no change in the pharmacokinetics. We also provide evidence that the pharmacokinetics did not change in two sequential administrations of the drug. Pharmacokinetic data are in agreement with previous reports.",

author = "{Van Hoogenhuijze}, J. and J. Lankelma and J. Stam and Pinedo, {H. M.}",

year = "1987",

doi = "10.1016/0277-5379(87)90283-5",

language = "English (US)",

volume = "23",

pages = "807--811",

journal = "European Journal of Cancer and Clinical Oncology",

issn = "0277-5379",

publisher = "Pergamon Press",

number = "6",

}

TY - JOUR

T1 - Unchanged pharmacokinetics of VP-16-213 (etoposide, NSC 141540) during concomitant administration of doxorubicin and cyclophosphamide

AU - Van Hoogenhuijze, J.

AU - Lankelma, J.

AU - Stam, J.

AU - Pinedo, H. M.

PY - 1987

Y1 - 1987

N2 - In patients with small-cell lung cancer VP-16-213 is often given in combination with doxorubicin and cyclophosphamide. Little is known about possible interactions between these drugs. Therefore we investigated in 7 patients the pharmacokinetics of VP-16-213, with and without the other two drugs. We found no change in the pharmacokinetics. We also provide evidence that the pharmacokinetics did not change in two sequential administrations of the drug. Pharmacokinetic data are in agreement with previous reports.

AB - In patients with small-cell lung cancer VP-16-213 is often given in combination with doxorubicin and cyclophosphamide. Little is known about possible interactions between these drugs. Therefore we investigated in 7 patients the pharmacokinetics of VP-16-213, with and without the other two drugs. We found no change in the pharmacokinetics. We also provide evidence that the pharmacokinetics did not change in two sequential administrations of the drug. Pharmacokinetic data are in agreement with previous reports.

UR - http://www.scopus.com/inward/record.url?scp=0023211990&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023211990&partnerID=8YFLogxK

U2 - 10.1016/0277-5379(87)90283-5

DO - 10.1016/0277-5379(87)90283-5

M3 - Article

C2 - 2820744

AN - SCOPUS:0023211990

SN - 0277-5379

VL - 23

SP - 807

EP - 811

JO - European Journal of Cancer and Clinical Oncology

JF - European Journal of Cancer and Clinical Oncology

IS - 6

ER -

Unchanged pharmacokinetics of VP-16-213 (etoposide, NSC 141540) during concomitant administration of doxorubicin and cyclophosphamide

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this